Optimising the M72/AS01E tuberculosis vaccine candidate phase 3 trial based on the phase 2b trial results

Affiliations

• ¹ Victorian Tuberculosis Program, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Level 5, 792 Elizabeth St, Melbourne, Victoria 3000, Australia; Department of Infectious Diseases, University of Melbourne, At the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia. Electronic address: katie.dale@mh.org.au.
• ² Victorian Tuberculosis Program, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Level 5, 792 Elizabeth St, Melbourne, Victoria 3000, Australia; Department of Infectious Diseases, University of Melbourne, At the Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Victoria 3000, Australia; Victorian Infectious Disease Service, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, 300 Grattan St, Parkville, Victoria 3052, Australia.